Emergent BioSolutions Inc.
EBS
$8.07
-$0.06-0.74%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -206.64% | 526.67% | -117.65% | 317.25% | -127.26% |
| Total Depreciation and Amortization | 0.43% | -0.43% | -7.48% | -2.31% | -1.52% |
| Total Amortization of Deferred Charges | 4.00% | 4.17% | 4.35% | 4.55% | 132.84% |
| Total Other Non-Cash Items | 1,110.00% | 162.50% | -127.12% | 38.82% | 118.32% |
| Change in Net Operating Assets | 200.74% | -185.06% | 180.62% | -39.16% | -230.03% |
| Cash from Operations | 3,478.26% | -102.16% | 1,050.00% | 85.98% | -151.98% |
| Capital Expenditure | -14.71% | -17.24% | 19.44% | -111.76% | 70.69% |
| Sale of Property, Plant, and Equipment | -- | -100.00% | -99.74% | 12,600.00% | -96.05% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -100.00% |
| Other Investing Activities | -- | -100.00% | -20.00% | -16.67% | -- |
| Cash from Investing | -14.71% | -119.77% | -71.09% | 108.04% | -74.46% |
| Total Debt Issued | -- | -- | -- | -- | -100.00% |
| Total Debt Repaid | -1,430.43% | -- | -- | -- | 100.00% |
| Issuance of Common Stock | 500.00% | -71.43% | 600.00% | -87.50% | -91.40% |
| Repurchase of Common Stock | -3.26% | -29.58% | -1,320.00% | -66.67% | 0.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -100.00% |
| Cash from Financing | -616.35% | -148.44% | -1,500.00% | -180.00% | 100.28% |
| Foreign Exchange rate Adjustments | 100.00% | -120.00% | 242.86% | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -83.94% | -118.44% | 150.42% | 192.91% | -159.48% |